Combination therapy with thalidomide plus dexamethasone for patients with reaped or refractory multiple myeloma and for patients on stable phase multiple myeloma
10.3760/cma.j.issn.1009-9921.2008.03.010
- VernacularTitle:沙利度胺联合地塞米松治疗复发和(或)难治及平台期多发性骨髓瘤疗效分析
- Author:
Lihong LI
;
Yanchen LI
;
Aijun LIU
;
Jing WANG
;
Yin WU
;
Wenming CHEN
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Drug therapy,combination
- From:
Journal of Leukemia & Lymphoma
2008;17(3):192-194,199
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of thalidomide in combination with dexamethasone (ID) in patients with relapsed or refractory multiple myeloma and in patients on stable phase. Methods Sixty-two patients with multiple myeloma were studied, include 25 with relapsed or refractory multiple myeloma, and 37 in stable phase. For the relapsed or refractory patients, thalidomide and dexamethasone was given at first three cycles, and then other regiments were given to no-response patients. For the all response patients, the second three cycles TD were enforced. On stable phase patients, thalidomide and dexamethasone were given as the second three cycles of relapsed or refractory patients. Then, thalidomide was given persistently until the disease relapse. Results All of the 25 relapsed or refractory patients were accepted the first 3 cycle TD treatment. The total response rate (VGPR+PR+MR) was 80 %. No complete remission (CR) and near CR(nCR) was gained. For the all response patients, the second three cycles TD were enforced. One patient achieved nCR. Thalidomide was given to all response patients. The median remission time was 6.8 (4～12) months. TD regimen was used to the 37 stable phase patients. The median remission time was 17.5 (8～26) months. The remission time of stable remission patients is longer then that of relapsed or refractory patients (P <0.001). Conclusion The combination of thalidomide and dexamethasone is a feasible and active regimen in the treatment of relapsed or refractory, and stable phase myeloma patients.
